The effects of estrogen and progestins on the vascular wall have drawn major medical attention, and significant controversy over various studies has been developed. Several experimental and observational studies have shown cardioprotective effects; however, prospective randomized trials showed an increase in cardiovascular events in postmenopausal women on estrogen/medroxyprogesterone acetate treatment. The most significant parameter for cardiovascular benefit of estrogen seems to be the interval since the onset of menopause. In the early postmenopausal years, estrogen has beneficial effects on the vascular wall by inhibition of atherosclerosis progression, whereas in the late postmenopause, adverse effects like upregulation of the plaque inflammatory processes and plaque instability may develop. The effects of progestins on the cardiovascular system are not as clear and may differ according to the choice of progestins that is used. The aim of this review is to summarize the effects of estrogen and progestins on the vascular wall and their clinical implications.
MinirioA.M., HeronM.P., MurphyS.L., KochanekK.D.; Centers for Disease Control and Prevention National Center for Health Statistics National Vital Statistics System. Deaths: final data for 2004.Natl Vital Stat Rep.2007; 55: 1–119.
2.
DubeyR.K., ImthurnB., BartonM., JacksonE.K.Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen.Cardiovasc Res.2005; 66: 295–306.
3.
StampferM.J., WillettW.C., ColditzG.A., RosnerB., SpeizerF.E., HennekensC.H.A prospective study of postmenopausal estrogen therapy and coronary heart disease.N Engl J Med.1985; 313: 1044–1049.
4.
GrodsteinF., MansonJ.E., ColditzG.A., WillettW.C., SpeizerF.E., StampferM.J.A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.Ann Intern Med.2000; 133: 933–941.
5.
GradyD., RubinS.M., PetittiD.B.Hormone therapy to prevent disease and prolong life in postmenopausal women.Ann Intern Med.1992; 117: 1016–1037.
6.
GradyD., HerringtonD., BittnerV.Cardiovascular disease outcomes during 6.8 years of hormone replacement therapy. Heart Estrogen/Progestin Replacement Study Follow-up (HERS-II).JAMA.2002; 288: 49–57.
7.
RossouwJ.E., AndersonG.L., PrenticeR.L.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women.JAMA.2002; 288: 321–333.
8.
GebbieA.What's new in hormone replacement therapy.Medicine.2007; 35: 529–532.
9.
MendelsohnM.E.Protective effects of estrogen on the cardiovascular system.Am J Cardiol.2002; 89(suppl): 12E–18E.
10.
Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the million women study.Lancet.2003; 362: 419–427.
11.
GilliganD.M., QuyyumiA.A., CannonR.O.IIIEffects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women.Circulation.1994; 89: 2545–2551.
12.
ImthurnB., RosselliM., JaegerA.W., KellerP.J., DubeyR.K.Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate.J Clin Endocrinol Metab.1997; 82: 388–394.
13.
CollinsP., ShayJ., JiangC., MossJ.Nitric oxide accounts for dose-dependent estrogen-mediated coronary relaxation after acute estrogen withdrawal.Circulation.1994; 90: 1964–1968.
14.
YlikorkalaO., CacciatoreB., PaakkariI., TikkanenM.J., ViinikkaL., ToivonenJ.The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane.Fertil Steril.1998; 69: 883–888.
15.
KavserK., RubanyiG.M.Potential cellular signaling mechanism mediating upregulation of endothelial nitric oxide production by estrogen.J Vasc Res.1997; 34: 229–236.
16.
ArnalJ.F., ClamensS., PechetC.Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production.Proc Natl Acad Sci U S A.1996; 93: 4108–4113.
17.
RussellK.S., HaynesM.P., SinhaD., ClerismeE., BenderJ.R.Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling.Proc Natl Acad Sci U S A.2000; 97: 5930–5935.
18.
HisamotoK., BenderJ.R.Vascular cell signaling by membrane estrogen receptors.Steroids.2005; 70: 382–387.
19.
SimonciniT., RabkinE., LiaoJ.K.Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells.Arterioscler Thromb Vasc Biol.2003; 23: 198–203.
20.
SchulzE., AnterE., ZouM.H., KeaneyJ.F.Jr.Estradiol mediated endothelial nitric oxide synthase association with heat shock protein 90 requires adenosine monophosphate-dependent protein kinase.Circulation.2005; 111: 3473–3480.
21.
ChesterA.H., JiangC., BorlandJ.A., YacoubM., CollinsP.Oestrogen relaxes human epicardial coronary arteries through non-endothelial dependent mechanisms.Coron Artery Dis.1995; 6: 417–422.
FélétouM., VanhoutteP.M.EDHF: new therapeutic targets?Pharmacol Res.2004; 49: 565–580.
24.
HermenegildoC., OviedoP.J., CanoA.Cyclooxygenases regulation by estradiol on endothelium.Curr Pharm Des.2006; 12: 205–215.
25.
SimonA., GariepyJ., ChironiG., MegnienJ.L., LevensonJ.Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk.J Hypertens.2002; 20: 159–169.
26.
NakamuraY., SuzukiY., MikiC.Estrogen receptors in atherosclerotic human aorta: inhibition of human vascular smooth muscle cell proliferation by estrogens.Mol Cell Endocrinol.2004; 219: 17–26.
BoyleE.M., VerrierE.D., SpiessB.D.Endothelial cell injury in cardiovascular surgery: the procoagulant response.Ann Thorac Surg.1996; 62: 1549–1557.
29.
TorryD.S., TorryR.J.Angiogenesis and the expression of vascular endothelial growth factor in endometrium and placenta.Am J Reprod Immunol.1997; 37: 21–29.
30.
SmithS.K.Angiogenesis, vascular endothelial growth factor and the endometrium.Hum Reprod Update.1998; 4: 509–519.
31.
RubanyiG.M., JohnsA., KauserK.Effects of estrogen on endothelial function and angiogenesis.Vascul Pharmacol.2002; 38: 89–98.
32.
ImanishiT., KobayashiK., HanoT., NishioI.Effect of estrogen on differentiation and senescence in endothelial progenitor cells derived from bone marrow in spontaneously hypertensive rats.Hypertens Res.2005; 28: 763–772.
33.
ImanishiT., KobayashiK., HanoT., NishioI.Estrogen reduces endothelial progentior cell senescence through augmentation of telomerase activity.J Hypertens.2005; 23: 1699–1706.
34.
ZhaoX., HuangL., YinY., FangY., ZhaoJ., ChenJ.Estrogen induces endothelial progenitor cells proliferation and migration by estrogen receptors and PI3K-dependent pathways.Microvasc Res.2008; 75: 45–52.
35.
LacutK., OgerE., Le GalG.; SARAH investigators. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein.Thromb Haemost.2003; 90: 124–131.
36.
O'BrienK.D., McDonaldT.O., ChaitA., AllenM.D., AlpersC.E.Neovascular expression of E-selectin, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content.Circulation.1996; 93: 672–682.
37.
ShifrenJ.L., RifaiN., DesindesS., McIlwainM., DorosG., MazerN.A comparison of the short-term effects of oral conjugated equine estrogens vs transdermal estradiol on C-reactive protein, other serum markers of inflammation and other hepatic proteins in naturally menopausal women [published online ahead of print February 26, 2008].J Clin Endocrin Metab. doi:10.1210/jc.2007-2193.
38.
ZangerD., YangB.K., ArdansJ.Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management.J Am Coll Cardiol.2000; 36: 1797–1802.
39.
StörkS., von SchackyC., AngererP.The effect of 17β-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized controlled trial.Atherosclerosis.2002; 165: 301–307.
40.
CushmanM., LegaultC., Barrett-ConnorE.Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestins Interventions (PEPI) study.Circulation.1999; 100: 717–722.
41.
StörkS., BaumannK., von SchackyC., AngererP.The effect of 17β-estradiol on MCP-1 serum levels in postmenopausal women.Cardiovasc Res.2002; 53: 642–649.
42.
ClarksonT.B.Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression.Menopause.2007; 14: 373–384.
43.
ZeguraB., Guzic-SalobirB., SebestjenM., KeberI.The effects of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.Menopause.2006; 13: 643–650.
44.
RificiV.A., KhachadurianA.K.The inhibition of low-density lipoprotein oxidation by 17-beta estradiol.Metabolism.1992; 41: 1110–1114.
45.
VihmaV., VehkavaaraS., Yki-JärvinenH., HohtariH., TikkanenM.J.Differential effects of oral and transdermal estradiol treatment on circulating estradiol fatty acid ester concentrations in postmenopausal women.J Clin Endocrinol Metab.2003; 88: 588–593.
46.
LamK.K., LeeY.M., HsiaoG., ChenS.Y., YenM.H.Estrogen therapy replenishes vascular tetrahydrobiopterin and reduces oxidative stress in ovariectomized rats.Menopause.2006; 13: 294–302.
47.
KarimR., MackW.J., LoboR.Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: estrogen in the prevention of atherosclerosis trial.Menopause.2005; 12: 366–373.
48.
SalpeterS.R., WalshJ.M., OrmistonT.M., GreyberE., BuckleyN.S., SalpeterE.E.Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women.Diabetes Obes Metab.2006; 8: 538–554.
49.
KernohanA.F.B., SattarN., HilditchT.Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes.Clin Endocrinol.2007; 66: 27–34.
50.
ZhuB.T., ConneyA.H.Functional role of estrogen metabolism in target cells: review and perspectives.Carcinogenesis.1998; 19: 1–37.
CushmanM., KullerL.H., PrenticeR.; Women's Health Initiative Investigators. Etrogen plus progestin and risk of venous thrombosis.JAMA.2004; 292: 1573–1580.
53.
CananicoM., OgerE., Plu-BureauG.; Estrogen and Thromboembolism Risk Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.Circulation.2007; 115: 840–845.
54.
AdamsM.R., KaplanJ.R., ManuckS.B.Inhibition of coronary artery atherosclerosis by 17-β estradiol in ovariectomized monkeys. Lack of an effect of added progesterone.Arteriosclerosis.1990; 10: 1051–1057.
ClarksonT.B., AnthonyM.S., WagnerJ.D.A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys.J Clin Endocrinol Metab.2001; 86: 5396–5404.
57.
MansonJ.E., HsiaJ., JohnsonK.C.Estrogen plus progestin and the risk of coronary heart disease.N Engl J Med.2003; 349: 523–534.
58.
HsiaJ., LangerR.D., MansonJ.E.Conjugated equine estrogens and coronary heart disease. The women's health initiative.Arch Intern Med.2006; 166: 357–365.
59.
GrodsteinF., MansonJ.E., StampferM.J.Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation.J Women's Health.2006; 15: 35–44.
60.
GompelA., BarlowD., RozenbergS., SkoubyS.O.Updating the EMAS 2004/2005 clinical recommendations on postmenopausal therapy following the recent publications: WHI and nurses' health study.Maturitas.2006; 55: 1–4.
61.
SalpeterS.R., WalshJ.M., GreyberE., SalpeterE.E.Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A metaanalysis.J Gen Intern Med.2006; 21: 363–366.
62.
HodisH.N., MackW.J., LoboR.A.Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial.Ann Intern Med.2001; 135: 939–953.
63.
LosordoD.W., KearneyM., KimE.A., JekanowskiJ., IsnerJ.M.Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women.Circulation.1994; 89: 1501–1510.
64.
PostW.S., Goldschmidt-ClermontP.J., WilhideC.C.Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system.Cardiovasc Res.1999; 43: 985–991.
65.
ShearmanA.M., CupplesL.A., DemissieS.Association between estrogen receptor-α gene variation and cardiovascular disease.JAMA.2003; 290: 2263–2270.
66.
OgawaS., EmiM., ShirakiM., HosoiT., OuchiY., InoueS.Association of estrogen receptor-beta (ESR2) gene polymorphism with blood pressure.J Hum Genet.2000; 45: 327–330.
67.
MatsubaraY., MurataM., KawanoK.Genotype distribution of estrogen receptor polymorphisms in men and postmenopausal women from healthy and coronary populations and its relation to serum lipid levels.Arterioscler Thromb Vasc Biol.1997; 17: 3006–3012.
68.
KarasR.H.Current controversies regarding the cardiovascular effects of hormone therapy.Clin Obstet Gynecol.2004; 47: 489–499.
69.
AikawaM., RabkinE., SugiyamaS.An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro.Circulation.2001; 103: 276–283.
70.
FukumotoY., LibbyP., RabkinE.Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits.Circulation.2001; 103: 993–999.
71.
CribbyM., Nordin-FredrikssonG., ShahP.K., YanoJ., ZhuJ., NilssonJ.Provastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization.Circulation.2001; 103: 926–933.
72.
Hild-PetitoS., StoufferR.L., BrennerR.M.Immunocytochemical localization of estradiol and progesterone receptors in the monkey ovary throughout the menstrual cycle.Endocrinology.1988; 123: 2896–2905.
73.
SellesJ., PoliniN., AlvarezC., MassheimerV.Nongenomic action of progesterone in rat aorta: role of nitric oxide and prostaglandins.Cell Signal.2002; 14: 431–436.
74.
HermenegildoC., OviedoP.J., Garcia-MartinezM.C., Garcia-PerezM.A., TarinJ.J., CanoA.Progestogens stimulate prostacyclin production by human endothelial cells.Hum Reprod.2005; 20: 1554–1561.
75.
RosanoG.M.C., LeonardoF., SarrelP.M., BealeC., De LucaF., CollinsP.Cyclical variation in paroxysmal supraventricular tachycardia in women.Lancet.1996; 347: 786–788.
76.
PedersenN.G., PedersenS.H., DalsgaardT., LundC.O., NilasL., OttesenB.Progestins used in hormonal replacement therapy display different effects in coronary arteries from New Zealand white rabbits.Maturitas.2004; 49: 304–314.
77.
ClarksonT.B., ApptS.E.MPA and postmenopausal coronary artery atherosclerosis revisited.Steroids.2003; 68: 941–951.
78.
SimonciniT., MannellaP., FornariL.Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells.Endocrinology.2004; 145: 5745–5756.
79.
LevineR.L., ChenS.J., DurandJ., ChenY.F., OparilS.Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery.Circulation.1996; 94: 2221–2227.
80.
HerkertO., KuhlH., SandowJ., BusseR., Schini-KerthV.B.Sex steroids used hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression. Role of the glucocorticoid receptor.Circulation.2001; 104: 826–831.
81.
Sitruk-WareR.Pharmacological profile of progestins.Maturitas.2004; 47: 277–283.
82.
Sitruk-WareR.Progestins and cardiovascular risk markers.Steroids.2000; 65: 651–658.
83.
The Writing Group for the PEPI Trial. Effects of androgen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin (PEPI) trial.JAMA.1995; 273: 199–208.
84.
CrookD., CustM.P., GangarK.F.Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins.Am J Obstet Gynecol.1992; 166: 950–955.
85.
SimonciniT., MannellaP., FornariL., CarusoA., VaroneG., GenazzaniA.R.In vitro effects of progesterone and progestins on vascular cells.Steroids.2003; 68: 831–836.
86.
WinklerU.H.Effects of progestins on cardiovascular diseases: the haemostatic system.Hum Reprod Update.1999; 5: 200–204.
